Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
The trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM). Unlike the mixed isomer clomifene (Clomid), enclomiphene is the active anti-estrogenic component without the estrogenic zuclomiphene isomer. Studied as a treatment for secondary hypogonadism that preserves fertility, unlike exogenous testosterone.
A neuropeptide that acts as the master regulator of the reproductive hormone axis. Kisspeptin neurons in the hypothalamus control the release of GnRH (gonadotropin-releasing hormone), which in turn drives LH and FSH production. Increasingly studied for fertility treatment, hypogonadism, and as a diagnostic tool for reproductive disorders. Also being explored for its role in emotional and sexual brain processing.
Blocks estrogen receptors in the hypothalamus, removing negative feedback on GnRH release. This increases pulsatile GnRH secretion, which stimulates pituitary LH and FSH production, driving endogenous testosterone synthesis while maintaining spermatogenesis.
Binds to the KISS1R (GPR54) receptor on GnRH neurons in the hypothalamus, triggering GnRH release. This stimulates the anterior pituitary to release LH and FSH, which drive testosterone production in males and ovulation in females. Kisspeptin is the upstream 'gatekeeper' of the entire HPG axis.
- Secondary hypogonadism treatment
- Testosterone optimization without TRT
- Post-cycle therapy (PCT)
- Fertility preservation in hypogonadal men
- Alternative to clomiphene with fewer estrogenic side effects
- Fertility treatment (investigational)
- Hypogonadism evaluation
- IVF protocols (as GnRH trigger alternative)
- Reproductive endocrinology research
- Libido and sexual function research
- Headache
- Nausea
- Hot flashes
- Visual disturbances (less common than with clomiphene)
- Not FDA-approved — regulatory status uncertain
- Injection site discomfort
- Headache and flushing
- Potential for ovarian hyperstimulation in women
- Short half-life requires frequent dosing or infusion
- Limited long-term safety data
Not FDA-approved. Repros Therapeutics (now Allergan) submitted NDA for Androxal but received a Complete Response Letter in 2015. Currently available through compounding pharmacies. Active interest from telehealth clinics as a TRT alternative.
Not FDA-approved. Active clinical trials at Imperial College London and other institutions for fertility applications. Being studied as a safer alternative to hCG triggers in IVF (lower risk of ovarian hyperstimulation syndrome). No US-approved formulation exists.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.